首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study
【24h】

Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study

机译:根据稀疏研究和贝叶斯先验的非房室文献资料开发伐昔洛韦的儿科人群药代动力学模型:模拟研究

获取原文
获取原文并翻译 | 示例
           

摘要

A preliminary population pharmacokinetic (PopPK) model of valacyclovir in children was developed from non-compartmental analysis (NCA) parameter values from literature, including several age groups, combined with Bayesian priors from a PopPK model of acyclovir, the active metabolite of valacyclovir, from literature too. Also a simulation study was carried out to evaluate the performance of various modelling choices related to the estimation of model parameters from NCA parameters originating from sparse PK studies. Assuming a one-compartment model with first order absorption, a mixed effects, meta-analysis approach was utilized which allows accounting the random intergroup variability, the detection of covariates and the application of informative Bayesian priors on the parameters. The conclusions from the simulation study calculating bias and precision for various cases, were that a model which takes explicitly into account the sampling schedule, performs better than a model using the theoretical expressions of calculating the NCA parameters. Also by using the geometric rather than the arithmetic means of NCA parameters, less biased results are obtained. These findings guided the choices for the valacyclovir model, for which informative priors from a PopPK model of acyclovir were applied for some of the parameters, in order to include a richer covariate model for clearance, not supported by the NCA dataset and a value for bioavailability. This preliminary valacyclovir model can be used in simulations to provide dosage recommendations for children of various ages and to help design more efficiently prospective clinical trials.
机译:从非房室分析(NCA)参数值(包括多个年龄段)文献中,结合儿童的非房室分析(NCA)参数值,开发了儿童伐昔洛韦的初步人群药代动力学(PopPK)模型,并结合了来自阿昔洛韦,伐昔洛韦的活性代谢产物阿昔洛韦的PopPK模型的贝叶斯先验知识。文学也。还进行了仿真研究,以评估与根据稀疏PK研究得出的NCA参数估算模型参数有关的各种建模选择的性能。假设具有一阶吸收的单室模型,则采用了一种混合效应的荟萃分析方法,该方法可以解决随机组间变异性,协变量的检测以及信息性贝叶斯先验在参数上的应用。通过仿真研究得出的各种情况下的偏差和精度的结论是,明确考虑了采样时间表的模型的性能要优于使用计算NCA参数的理论表达式的模型。同样通过使用几何而非NCA参数的算术手段,可以获得较少的偏差结果。这些发现指导了伐昔洛韦模型的选择,其中将阿昔洛韦的PopPK模型的先验信息应用于某些参数,以便包括NCA数据集不支持的更丰富的清除协变量模型和生物利用度值。初步的伐昔洛韦模型可用于模拟,以为不同年龄的儿童提供剂量建议,并帮助设计更有效的前瞻性临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号